# ProPhase Labs, Inc.: overview PRPH · OTC · CIK 868278 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/prph.md) · [Financials](/companies/prph/financials.md) · [Filings](/companies/prph/filings.md) · [Insiders](/companies/prph/insiders.md) Latest reported revenue: [$1.0m](/filings/0001493152-26-039224.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 19, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-039224). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [1,416](/filings/0000868278-25-000017.md) | [1,494 d](/filings/0000868278-26-000005.md) | [1,431](/filings/0001493152-26-032658.md) | [1,247](/filings/0001493152-26-039224.md) | [883](/filings/0000868278-25-000017.md) | [784 d](/filings/0000868278-26-000005.md) | [1,169](/filings/0001493152-26-032658.md) | [1,011](/filings/0001493152-26-039224.md) | | Gross margin | % | [15.2%](/filings/0000868278-25-000017.md) | [(10.0%) d](/filings/0000868278-26-000005.md) | [36.8%](/filings/0001493152-26-032658.md) | [58.9%](/filings/0001493152-26-039224.md) | [(13.9%)](/filings/0000868278-25-000017.md) | [31.5% d](/filings/0000868278-26-000005.md) | [25.2%](/filings/0001493152-26-032658.md) | [22.4%](/filings/0001493152-26-039224.md) | | Operating margin | % | [(457.6%)](/filings/0000868278-25-000017.md) | [(1157.3%) d](/filings/0000868278-26-000005.md) | [(256.0%)](/filings/0001493152-26-032658.md) | [(312.3%)](/filings/0001493152-26-039224.md) | [(539.5%)](/filings/0000868278-25-000017.md) | [(730.4%) d](/filings/0000868278-26-000005.md) | [(207.5%)](/filings/0001493152-26-032658.md) | [(261.6%)](/filings/0001493152-26-039224.md) | | Net margin | % | [(465.2%)](/filings/0000868278-25-000017.md) | [(2299.8%) d](/filings/0000868278-26-000005.md) | [277.1%](/filings/0001493152-26-032658.md) | [(358.6%)](/filings/0001493152-26-039224.md) | [(774.5%)](/filings/0000868278-25-000017.md) | [(943.6%) d](/filings/0000868278-26-000005.md) | [(442.7%)](/filings/0001493152-26-032658.md) | [(301.8%)](/filings/0001493152-26-039224.md) | | Diluted EPS | $ per share | [(0.35)](/filings/0000868278-25-000017.md) | not reported | [1.13](/filings/0001493152-26-032658.md) | [(1.08)](/filings/0001493152-26-039224.md) | [(0.16)](/filings/0000868278-25-000017.md) | not reported | [(0.42)](/filings/0001493152-26-032658.md) | [(0.22)](/filings/0001493152-26-039224.md) | | Free cash flow | $k | [(4,039) d](/filings/0000868278-25-000017.md) | [(3,558) d](/filings/0000868278-26-000005.md) | [(3,381)](/filings/0001493152-26-032658.md) | [(247) d](/filings/0001493152-26-039224.md) | [(3,486) d](/filings/0000868278-25-000017.md) | [(1,230) d](/filings/0000868278-26-000005.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [79.0](/filings/0000868278-23-000004.md) | [123](/filings/0000868278-24-000004.md) | [35.0](/filings/0000868278-25-000003.md) | [6.8](/filings/0000868278-26-000005.md) | [4.3](/filings/0000868278-26-000005.md) | | Gross margin | % | [53.1%](/filings/0000868278-23-000004.md) | [57.6%](/filings/0000868278-24-000004.md) | [44.5%](/filings/0000868278-25-000003.md) | [(2.2%)](/filings/0000868278-26-000005.md) | [31.9%](/filings/0000868278-26-000005.md) | | Operating margin | % | [12.4%](/filings/0000868278-23-000004.md) | [19.2%](/filings/0000868278-24-000004.md) | [(60.7%)](/filings/0000868278-25-000003.md) | [(570.6%)](/filings/0000868278-26-000005.md) | [(415.4%)](/filings/0000868278-26-000005.md) | | Net margin | % | [7.9%](/filings/0000868278-23-000004.md) | [15.1%](/filings/0000868278-24-000004.md) | [(48.0%)](/filings/0000868278-25-000003.md) | [(788.2%)](/filings/0000868278-26-000005.md) | [(339.3%)](/filings/0000868278-26-000005.md) | | Diluted EPS | $ per share | [0.40](/filings/0000868278-23-000004.md) | [1.02](/filings/0000868278-24-000004.md) | [(0.98)](/filings/0000868278-25-000003.md) | [(26.68)](/filings/0000868278-26-000005.md) | [(1.74)](/filings/0000868278-26-000005.md) | | Free cash flow | $m | [(17.9)](/filings/0000868278-23-000004.md) | [24.6](/filings/0000868278-24-000004.md) | [(14.0)](/filings/0000868278-25-000003.md) | [(18.4)](/filings/0000868278-26-000005.md) | [(8.3)](/filings/0000868278-26-000005.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/prph/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [CoreCap Advisors, LLC](/funds/1902501.md) | 2026-06-30 | $1 | 10 | | Unchanged | | [Farther Finance Advisors, LLC](/funds/1992825.md) | 2026-06-30 | $1 | 10 | | Unchanged | ## Recent filings [All 735 filings](/companies/prph/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-19 | 20:31 ET | [10-Q](/filings/0001493152-26-039224.md) | Quarterly report, period 2026-06-30 | 0001493152-26-039224 | | 2026-08-06 | 21:00 ET | [8-K](/filings/0001493152-26-036383.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001493152-26-036383 | | 2026-07-09 | 19:12 ET | [10-Q/A](/filings/0001493152-26-032658.md) | Quarterly report, amended, period 2026-03-31 | 0001493152-26-032658 | | 2026-07-07 | 13:23 ET | [10-Q/A](/filings/0001493152-26-032269.md) | Quarterly report, amended, period 2026-03-31 | 0001493152-26-032269 | | 2026-06-30 | 20:50 ET | [10-Q](/filings/0001493152-26-031301.md) | Quarterly report, period 2026-03-31 | 0001493152-26-031301 | | 2026-06-01 | 21:13 ET | [10-K](/filings/0000868278-26-000005.md) | Annual report, period 2025-12-31 | 0000868278-26-000005 | | 2026-02-13 | 22:15 ET | [8-K](/filings/0001493152-26-006784.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-006784 | | 2026-02-13 | 22:15 ET | [8-K](/filings/0001493152-26-006785.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-006785 | | 2026-01-27 | 16:06 ET | [8-K](/filings/0001493152-26-003724.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-003724 | | 2026-01-23 | 22:20 ET | [8-K](/filings/0001493152-26-003460.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-003460 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000868278-26-000005.md), filed Jun 1, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/364a20ed-8018-483d-81da-fa9bee1277e3) ## About the filer - CIK: 868278 - Tickers: PRPH - Exchange: OTC - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.